OBJECTIVES Detection of activating epidermal growth factor receptor (EGFR) mutation is crucial for individualized treatment of advanced non-small-cell lung cancer (NSCLC). However little is known about how biopsy technique affects the detection rate of EGFR mutations. This retrospective, single center study evaluated the detection rate of EGFR mutations in tissue obtained by bronchoscopic cryobiopsy and compared this to other standard tissue sampling techniques. MATERIALS AND METHODS We retrospectively analyzed 414 patients with histologically confirmed NSCLC and known EGFR mutation status between 3/2008-7/2014. Tumor specimens obtained by tissue preserving bronchoscopic cryobiopsy were compared to those obtained by other techniques. RESULTS AND CONCLUSION Analysis of bronchoscopic cryobiopsy tissue detected 29 activating EGFR mutations in 27 (21.6 %) out of 125 patients, while analysis of tissue obtained by non-cryobiopsy techniques (bronchoscopic forceps biopsies, fine needle aspiration, imaging guided transthoracical and surgical procedures) detected 42 EGFR mutations in 40 (13.8 %) out of 298 patients (p < 0.05). Cryobiopsy increased detection rate of EGFR mutations in central tumors compared with forceps biopsy (19.6 % versus 6.5 %, p < 0.05), while an insignificant trend was detected also for peripheral tumors (33.3 % versus 26.9 %). Bronchosopic cryobiopsy increases the detection rate of activating EGFR mutations in NSCLC in comparison to other tissue sampling techniques. This will help to optimize individualized treatment of patients with advanced tumors. Because of the retrospective nature of this analysis, a prospective trial is mandatory for final assessment.

中文翻译：

---

低温活检可提高非小细胞肺癌中EGFR的检出率。

目的检测活化的表皮生长因子受体（EGFR）突变对于晚期非小细胞肺癌（NSCLC）的个体化治疗至关重要。然而，对于活检技术如何影响EGFR突变的检测率知之甚少。这项回顾性单中心研究评估了通过支气管镜低温活检获得的组织中EGFR突变的检出率，并将其与其他标准组织采样技术进行了比较。材料与方法我们回顾性分析了3 / 2008-7 / 2014之间经组织学确认为NSCLC且已知EGFR突变状态的414例患者。将通过组织支气管镜低温活检获得的肿瘤标本与通过其他技术获得的肿瘤标本进行了比较。结果与结论在125例患者中，支气管镜冷冻活检组织分析检测到29例激活的EGFR突变，占27例（21.6％），同时分析了非冷冻活检技术获得的组织（支气管镜钳活检，细针穿刺，影像引导下经胸和外科手术）在298位患者中有40位（13.8％）检测到42个EGFR突变（p <0.05）。与镊子活检相比，低温活检增加了中心肿瘤中EGFR突变的检出率（19.6％对6.5％，p <0.05），而周围肿瘤也未见明显趋势（33.3％对26.9％）。与其他组织采样技术相比，支气管镜低温活检可提高NSCLC中激活EGFR突变的检测率。这将有助于优化晚期肿瘤患者的个体化治疗。